Item 2. Properties
ITEM 2 .
PROPERTIES.
Our facilities in Israel, which house our research and development and certain production
and management functions, are located in Jerusalem, Israel. Most of our clinical development, clinical operations and regulatory functions
are located in the United States. Under a Lease Agreement with Unihead Biopark Ltd. as of December 31, 2022, we are leasing approximately
622 square meters of office and laboratory space pursuant to a lease agreement that will expire on June 30, 2023. Of the 622 square meters
leased, we utilize approximately 527 square meters for our operations and have agreed to sublease the remaining approximately 95 square
meters to a third-party until June 2023.
We believe that our current office and laboratory space in Israel is sufficient to
meet our anticipated needs for the foreseeable future and is suitable for the conduct of our business. We believe that suitable additional
space would be available if required in the future on commercially reasonable terms.
ITEM 3 .
LEGAL PROCEEDINGS.
We are not currently a party to any material legal proceedings.
ITEM 4 .
MINE SAFETY DISCLOSURES.
Not applicable.
77
PART II
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.